Reportable Diseases

Main Content

Reportable Cancer List DX 10/2021 or later

REPORTABLE CASES – MISSISSIPPI
For cases diagnosed 10/1/2021 and after

The following lists are intended to assist you, as the reporter, in identifying the reportable neoplasms for your facility. Any reportable neoplasms diagnosed on or after January 1, 1996 should be reported to the Mississippi Cancer Registry.

REPORTABLE NEOPLASMS

• Malignant neoplasms (exclusions noted below)
• Benign and borderline neoplasms of the central nervous system (Cases diagnosed on or after January 1, 2004)
• Pilocytic/juvenile astrocytoma listed as 9421/1 in ICD-O-3, is reportable, and should be coded to 9421/3.
• Squamous intraepithelial neoplasia grade III of vulva [VIN], vagina [VAIN], and anus [AIN] beginning with 2001 cases.
• Carcinoid, NOS of the appendix is reportable and should be coded 8240/3 (Cases diagnosed on or after January 1, 2015)
• Gastrointestinal Stromal Tumor (GIST), NOS (Cases diagnosed January 1, 2021 and later).
• Thymoma, NOS with multiple tumor foci and/or metastasis to lymph nodes or distant sites.
• GIST, NOS with multiple tumor foci and/or metastatic to lymph nodes or distant sites (Prior to January 1, 2021)

These are just some highlighted reportable conditions. For all reportable histologies, refer to https://www.naaccr.org/icdo3/#1582820761121-27c484fc-46a7 for the lists of reportable conditions reportable as of January 1, 2022

NON-REPORTABLE NEOPLASMS

• Basal and squamous cell carcinomas of the skin (ICD-O-3 Histologies 8090-8110)
• Epithelial carcinomas of the skin (ICD-O-3 Histologies 8010-8046)
• Papillary and squamous cell carcinomas of the skin (ICD-O-3 Histologies 8050-8084)
• Malignant neoplasms, NOS of the skin (ICD-O-3 Histologies 8000-8005)
• Carcinoma in-situ of the cervix
• Intraepithelial neoplasms of the cervix (ICD-O-3 Histology 8077/2) or prostate (ICD-O-3 Histology 8148/2)
• Borderline cystadenomas (ICD-O-3 Histologies 8442, 8451, 8462, 8472, 8473), of the ovaries with behavior code “1” are not collected as of January 1, 2001
• Cyst, brain or CNS tumor that does not have an ICD-O-3 code as of January 1, 2004
• Thymoma, NOS that are not stated to be malignant and are a single tumor with no metastasis to nodes or distant sites.

These are just some highlighted non-reportable conditions. For all reportable/non-reportable histologies, refer to https://www.naaccr.org/icdo3/#1582820761121-27c484fc-46a7 for the lists of reportable/non-reportable conditions as of January 1, 2022

AMBIGUOUS TERMINOLOGY

Terms That Constitute a Diagnosis**

Terms That Do Not Constitute a Diagnosis

Apparent(ly)

Cannot be ruled out

Appears to

Equivocal

Comparable with

Possible

Compatible with

Potentially malignant

Consistent with

Questionable

Favor(s)

Rule out

Malignant appearing

Suggests

Most likely

Worrisome

Presumed

 

Probable
Suspect
Suspicious
Typical of
Tumor (beginning with 2004 diagnosis and only for C70.0-C72.9, C75.1-C75.3)

Neoplasm (beginning with 2004 diagnosis and only for C70.0-C72.9, C75.1-C75.3)

** Do not substitute synonyms such as “supposed” for “presumed” or “equal” for “comparable.” Do not substitute “likely” for “most likely.” Use on the exact words on the list.

Exceptions:
• If a cytology is reported using any ambiguous term, do not interpret it as a diagnosis of cancer. Abstract the case only if a positive biopsy or a physician’s clinical impression of cancer supports the cytology findings.

• Genetic findings in the absence of pathologic or clinical evidence of reportable disease are indicative of risk only and do not constitute a diagnosis.

COMPREHENSIVE ICD-10-CM CASEFINDING CODE LIST FOR REPORTABLE TUMORS

ICD-10-CM Codes

Explanation of Codes

C00._-C43._, C4A._, C45._- C48._, C49._ - C96._

Malignant neoplasms (excluding category C44 and C49.A), stated or presumed to be primary (of specified site) and certain specified histologies 1

NEW for 2018:
C96.20 Malignant mast cell neoplasm, unspecified
C96.21 Aggressive systemic mastocytosis
C96.22 mast cell sarcoma C96.29 Other malignant cell neoplasm
C96.29 Other malignant cell neoplasm

C44.00, C44.09

Unspecified/other malignant neoplasm of skin of lip

C44.10_, C44.19_

Unspecified/other malignant neoplasm of skin of eyelid

C44.13_

Sebaceous cell carcinoma of the skin of eyelid (Effective 10/1/2018)

C44.20_, C44.29_

Unspecified/other malignant neoplasm skin of ear and external auricular canal

C44.30_, C44.39_

Unspecified/other malignant neoplasm of skin of other/unspecified parts of face

C44.40, C44.49

Unspecified/other malignant neoplasm of skin of scalp & neck

C44.50_, C44.59_

Unspecified/other malignant neoplasm of skin of trunk

C44.60_, C44.69_

Unspecified/other malignant neoplasm of skin of upper limb, incl. shoulder

C44.70_, C44.79_

Unspecified/other malignant neoplasm of skin of lower limb, including hip

C44.80, C44.89

Unspecified/other malignant neoplasm of skin of overlapping sites of skin

C44.90, C44.99

Unspecified/other malignant neoplasm of skin of unspecified sites of skin

C49.A_

Gastrointestinal Stromal Tumors

Note: All GIST are reportable beginning 1/1/2021.

D00._ – D09._

In-situ neoplasms (Note: Carcinoma in situ of the cervix (CIN III-8077/2) and Prostatic Intraepithelial Carcinoma (PIN III-8148/2) are not reportable).

D18.02

Hemangioma of intracranial structures and any site

D32._

Benign neoplasm of meninges (cerebral, spinal and unspecified)

D33._

Benign neoplasm of brain and other parts of central nervous system

D35.2 - D35.4

Benign neoplasm of pituitary gland, craniopharyngeal duct and pineal gland

D42._, D43._

Neoplasm of uncertain or unknown behavior of meninges, brain, CNS

D44.3 – D44.5

Neoplasm of uncertain or unknown behavior of pituitary gland, craniopharyngeal duct and pineal gland

D45

Polycythemia vera (9950/3)

D46._

Myelodysplastic syndromes (9980, 9982, 9983, 9985, 9986, 9989, 9991, 9992)

D47.02

Systemic mastocytosis

D47.1

Chronic myeloproliferative disease (9960/3, 9963/3)

D47.3

Essential (hemorrhagic) thrombocythemia (9962/3)

Includes Essential thrombocytosis, idiopathic hemorrhagic thrombocythemia

D47.4

Osteomyelofibrosis (9961/3)

Includes: Chronic idiopathic myelofibrosis, Myelofibrosis (idiopathic) (with myeloid metaplasia), myelosclerosis (megakaryocytic) with myeloid metaplasia), secondary myelofibrosis in myeloproliferative disease

D47.Z_

Neoplasm of uncertain behavior of lymphoid, hematopoietic and related tissue, unspecified (9960/3, 9971/3, 9931/3)

D47.9

Neoplasm of uncertain behavior of lymphoid, hematopoietic and related tissue, unspecified (9931/3)

D49.6, D49.7

Neoplasm of unspecified behavior of brain, endocrine glands and other CNS

D72.110

Idiopathic hypereosinophilic syndrome [HES]

D72.111

Lymphocytic Variant Hypereosinophilic Syndrome [LHES]

D72.118

Other hypereosinophilic syndrome

D72.119

Hypereosinophilic syndrome

R85.614

Cytologic evidence of malignancy on smear of anus

R87.614

Cytologic evidence of malignancy on smear of cervix

R87.624

Cytologic evidence of malignancy on smear of vagina

1 Note: Pilocytic/juvenile astrocytoma M-9421 moved from behavior /3 (malignant) to /1 (borderline malignancy) in ICD-O-3. However, these cases should be reported and behavior coded as /3 (malignant).

SUPPLEMENTAL CASEFINDING LIST TO BE SCREENED FOR REPORTABLE CONDITIONS

Cases with the following codes should be screened as time allows. Experience has shown that use of this supplemental list increases casefinding for benign brain and CNS, hematopoietic neoplasms and other reportable diseases

ICD-10-CM Codes

Explanation of Codes

B20

Human immunodeficiency virus [HIV] disease with other diseases Note: Excludes HIV with malignancy (B21), see reportable list

B97.33, B97.34, B97.35

Human T-cell lymphotrophic virus,( type I [HTLV-1], type II [HTLV-II], type 2 [HIV 2]) as the cause of diseases classified elsewhere

B97.7

Papillomarvirus as the cause of diseases classified elsewhere

C44.01, C44.02

Basal/squamous cell carcinoma of skin of lip

C44.11_, C44.12_

Basal/squamous cell carcinoma of skin of eyelid

C44.21_, C44.22_

Basal/squamous cell carcinoma of skin of ear and external auricular canal

C44.31_, C44.32_

Basal/squamous cell carcinoma of skin of other and unspecified parts of face

C44.41, C44.42

Basal/squamous cell carcinoma of skin of scalp and neck

C44.51_, C44.52_

Basal/squamous cell carcinoma of skin of trunk

C44.61_, C44.62_

Basal/squamous cell carcinoma of skin of upper limb, including shoulder

C44.71_, C44.72_

Basal/squamous cell carcinoma of skin of lower limb, including hip

C44.81, C44.82

Basal/squamous cell carcinoma of skin of overlapping sites of skin

C44.91, C44.92

Basal/squamous cell carcinoma of skin of unspecified sites of skin

D10._ – D31._, D34, D35.0, D35.1, D35.5_ D35.9, D36.__

Benign neoplasms (see “must collect” list for reportable benign neoplasms) Note: Screen for incorrectly coded

D3A._

Benign carcinoid tumors

D37._ – D41._

Neoplasms of uncertain or unknown behavior (see “must collect” list for reportable neoplasms of uncertain or unknown behavior) Note: Screen for incorrectly coded malignancies

D44.0 – D44.2, D44.6-D44.9

Neoplasm of uncertain or unknown behavior of other endocrine glands (see “must collect” list for D44.3-D44.5) Note: Screen for incorrectly coded malignancies

D47.01

Cutaneous mastocytosis (9740/1)

Note: Effective 10/1/2017

C47.09

Other mast cell neoplasms of uncertain behavior

Note: Effective 10/1/2017

D47.2

Monoclonal gammopathy Note: Screen for incorrectly coded Waldenstrom’s macroglobulinemia

D47.Z2

Castleman disease

D48._

Neoplasm of uncertain behavior of other and unspecified sites

D49.0 – D49.9

Neoplasm of unspecified behavior (except for D49.6 and D49.7)

D61.1

Drug-induced aplastic anemia (also known as “aplastic anemia due to antineoplastic chemotherapy”)

D61.810

Anemia due to antineoplastic chemotherapy

D61.82

Myelophthisis

D63.0

Anemia in neoplastic disease

D64.81

Anemia due to antineoplastic chemotherapy

D69.49, D69.59, D69.6

Other thrombocytopenia Note: Screen for incorrectly coded thrombocythemia

D70.1

Agranulocytosis secondary to cancer chemotherapy

D75.81

Myelofibrosis (note: this is not primary myelofibrosis [9961/3])

D76._

Other specified diseases with participation of lymphoreticular and reticulohistiocytic tissue

D89.0, D89.1

Other disorders involving the immune mechanism, not elsewhere classified Note: Review for miscodes

D89.4_

Mast cell activation syndrome and related disorders

Note: effective 10/1/2016

E08

Diabetes mellitus due to underlying condition

E31.2_

Multiple endocrine neoplasia [MEN] syndromes

E34.0

Carcinoid syndrome

E83.52

Hypercalcemia

E88.09

Other disorders of plasma-protein metabolism, not elsewhere classified

E88.3

Tumor lysis syndrome (following antineoplastic chemotherapy)

G13.0

Paraneoplastic neuromyopathy and neuropathy

G13.1

Other systemic atrophy primarily affecting central nervous system in neoplastic disease

G32.8_

Other specified degenerative disorders of nervous system in diseases classified elsewhere

G53

Cranial nerve disorders in diseases classified elsewhere

Note: Code first underlying neoplasm (C00-C49)

G55

Nerve root and plexus compressions in diseases classified elsewhere

ICD-10-CM coding instruction note: code also underlying disease, such as neoplasm (C00-D49)

G63

Polyneuropathy in diseases classified elsewhere

G73.1

Lambert-Eaton syndrome in neoplastic disease

G89.3

Neoplasm related pain (acute)(chronic)

G99.2

Myelopathy in disease classified elsewhere

H47.42

Disorders of optic chiasms in (due to) neoplasm

H47.52_

Disorders of visual pathways in (due to) neoplasm

H47.63_

Diorders of visual cortex in (due to) neoplasm

J34.81

Nasal mucositis (ulcerative)

J91.0

Malignant pleural effusion

J93.12

Secondary spontaneous pneumothorax

K12.31

Oral mucositis (ulcerative) due to antineoplastic therapy

K12.33

Oral mucositis (ulcerative) due to radiation

K22.711

Barrett’s esophagus with high grade dysplasia

K62.7

Radiation proctitis

K62.82

Dysplasia of anus (AIN I and AIN II)

K92.81

Gastrointestinal mucositis (ulcerated) (due to antineoplastic therapy)

M36.0

Dermato(poly)myositis in neoplastic disease

M36.1

Arthropathy in neoplastic disease

M84.5_

Pathologic fracture in neoplastic disease

M90.6_

Osteitis deformans in neoplastic disease

N42.3

Dysplasia of prostate (PIN I and PIN II)

N76.81

Mucositis (ulcerative) of vagina or vulva

N87._

Dysplasia of cervix uteri (CIN I and CIN II)

N89.0, N89.1, N89.3

Vaginal dysplasia (VIN I and VIN II)

N90.0, N90.1, N90.3

Vulvar dysplasia (VAIN I and VAIN II)

O01._

Hydatidiform mole Note: Benign tumor that can become malignant. If malignant, report as Choriocarcinoma (9100/3, ) malignancy code in the C00- C97 range

O9A.1_

Malignant neoplasm complicating pregnancy, childbirth and the puerperium

P04.11

Newborn affected by maternal antineoplastic chemotherapy

Note: Effective 10/1/2018

P04.12

Newborn affected by maternal cytotoxic drugs

Note: Effective 10/1/2018

Q85.0_

Neurofibromatosis (nonmalignant) (9540/1) Note: Neurofibromatosis is not cancer. These tumors can be precursors to acoustic neuromas, which are reportable

R18.0

Malignant ascites

R53.0

Neoplastic (malignant) related fatigue

R59._

Enlarged lymph nodes

R85.6_

Abnormal findings on cytological and histological examination of digestive organs

R87.61_, R87.62_

Abnormal findings on cytological/histological examination of female genital organs

R92._

Abnormal findings on diagnostic imaging of breast

R97._

Abnormal tumor markers

T38.6_

Poisoning by antigonadotropins, antiestrogens, antiandrogens, not elsewhere classified

T38.8_, T38.9_

Poisoning by hormones and their synthetic substitutes

T45.1_

Poisoning by, adverse effect of and under dosing of antineoplastic and immunosuppressive drugs

T45.8_, T45.9_

Poisoning by primary systemic and hematological agent, unspecified

T66

Unspecified effects of radiation

T80.1

Vascular complications following infusion, transfusion and therapeutic injection

T80.2_

Infections following infusion, transfusion and therapeutic injection

T80.810

Extravasation of vesicant antineoplastic chemotherapy

T80.818

Extravasation of other vesicant agent

T86.0

Complications of bone marrow transplant

Y63.2

Overdose of radiation given during therapy

Y84.2

Radiological procedure and radiotherapy as the cause of abnormal reaction of the patient, or of later complication, without mention of misadventure at the time of the procedure

Z03.89

Encounter for observation for other suspected diseases and conditions ruled out

Z08

Encounter for follow-up examination after completed treatment for malignant neoplasm

Z12._

Encounter for screening for malignant neoplasms

Z13.0

Encounter of screening for diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism

Z15.0

Genetic susceptibility to malignant neoplasm

Z17.0, Z17.1

Estrogen receptor positive and negative status

Z40.0_

Encounter for prophylactic surgery for risk factors related to malignant neoplasms

Z42.1

Encounter for breast reconstruction following mastectomy

Z48.290

Encounter for aftercare following bone marrow transplant

Z48.3

Aftercare following care for neoplasm

Z51.0

Encounter for antineoplastic radiation therapy

Z51.1_

Encounter for antineoplastic chemotherapy and immunotherapy

Z51.5, Z51.89

Encounter for palliative care and other specified aftercare

Z79.81_

Long term (current) use of agents affecting estrogen receptors and estrogen levels

Z80._

Family history of primary malignant neoplasm

Z85._

Personal history of malignant neoplasm

Z86.0_, Z86.01_, Z86.03

Personal history of in situ and benign neoplasms and neoplasms of uncertain behavior

Z92.21, Z29.23, Z92.25. Z92.3

Personal history of antineoplastic chemotherapy, estrogen therapy, immunosuppression therapy or irradiation (radiation)

Z94.81, Z94.84

Bone marrow and stem cell transplant status